<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

Novel Agents Promise Relief From Hematologic Side Effects

NTP Plans Look At Radiation, Viruses, In Carcinogen Report.

Interferon Alpha-2B Effective For Malignant Melanoma

FASEB Urges Congress To Fund Stem Cell Research.

International Group Plans Survey On Thrombosis Risk

HHS Forms Rural Task Force To Study, Improve Programs.

NCI-Approved Clinical Trials Listed For June 2001

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

Quality Oncology Wins Pilot Contract For Cancer Management In Fla.

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.